Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN3017 |
Synonyms | |
Therapy Description |
GEN3017 is a bispecific antibody targeting CD3 and TNFRSF8, which potentially induces T-cell activation and subsequent cytotoxicity of TNFRSF8-expressing tumor cells (Blood (2022) 140 (Supplement 1): 3153–3154). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN3017 | GEN 3017|GEN-3017 | CD3 Antibody 99 | GEN3017 is a bispecific antibody targeting CD3 and TNFRSF8, which potentially induces T-cell activation and subsequent cytotoxicity of TNFRSF8-expressing tumor cells (Blood (2022) 140 (Supplement 1): 3153–3154). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06018129 | Phase Ib/II | GEN3017 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |